SQZ Biotechnologies (NYSE:SQZ) Short Interest Update

0

SQZ Biotechnologies (NYSE:SQZ – Get Rating) was the target of a sharp drop in short interest in May. As of May 31, short interest totaled 1,610,000 shares, down 15.7% from the May 15 total of 1,910,000 shares. Based on an average daily trading volume of 492,900 shares, the short interest ratio is currently 3.3 days. Currently, 7.9% of the company’s shares are shorted.

In related news, Director Klavs F. Jensen acquired 14,326 shares of the company’s shares in a transaction on Wednesday, May 25. The stock was purchased at an average price of $3.52 per share for a total value of $50,427.52. Following the acquisition, the Director now owns 353,309 shares of the Company, valued at approximately $1,243,647.68. The purchase was disclosed in a document filed with the SEC, which can be accessed at this link. Insiders own 18.00% of the company’s shares.

A number of institutional investors have been buying and selling shares of the stock recently. 683 Capital Management LLC increased its stake in SQZ Biotechnologies by 9.4% in the fourth quarter. 683 Capital Management LLC now owns 1,852,135 shares of the company’s stock valued at $16,540,000 after purchasing an additional 159,748 shares last quarter. NanoDimension Inc. acquired a new stake in SQZ Biotechnologies stock valued at $12,906,000 during the fourth quarter. BlackRock Inc. increased its position in shares of SQZ Biotechnologies by 13.1% in the fourth quarter. BlackRock Inc. now owns 1,413,870 shares of the company’s stock valued at $12,625,000 after purchasing an additional 163,780 shares last quarter. State Street Corp increased its position in SQZ Biotechnologies by 7.2% in the fourth quarter. State Street Corp now owns 350,617 shares of the company’s stock valued at $3,131,000 after purchasing an additional 23,405 shares last quarter. Finally, Geode Capital Management LLC increased its position in shares of SQZ Biotechnologies by 17.2% during the fourth quarter. Geode Capital Management LLC now owns 303,500 shares of the company’s stock valued at $2,710,000 after purchasing an additional 44,451 shares last quarter. Institutional investors and hedge funds own 66.56% of the company’s shares.

Separately, Chardan Capital took over coverage of SQZ Biotechnologies in a report Wednesday, May 25. They issued a “buy” rating and a price target of $17.00 on the company.

SQZ Biotechnologies shares rose $0.10 during Friday trade to hit $3.16. The stock had a trading volume of 5,067 shares compared to an average volume of 153,442. SQZ Biotechnologies has a 1 year low of $2.73 and a 1 year high of $16.17. The stock’s 50-day moving average is $3.54 and the two-hundred-day moving average is $6.01.

SQZ Biotechnologies (NYSE:SQZ – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. As a group, equity analysts are forecasting that SQZ Biotechnologies will report earnings per share of -2.87 for the current fiscal year.

About SQZ Biotechnologies (received rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing cell therapies for patients suffering from cancer, autoimmune diseases, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.

Further reading



Receive News & Reviews for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Comments are closed.